The three-party consortium will use Vaxxas’ needle-free technology to develop a seasonal and pandemic flu vaccine. Read More >>
Will leverage PolyPeptide’s peptide manufacturing and development services and Lifecore’s formulation, fill/finish, and packaging services.
Follows transition to private ownership under Novo Holdings and recent establishment of its global headquarters in Tampa, FL.
Will combine AI technology with 3DP innovation in drug delivery.
